Pre-Open Stock Movers 10/23: (SAVA) (SLDB) (SAM) Higher; (LLNW) (USX) (INTC) Lower (more...)

October 23, 2020 9:27 AM

Today's Pre-Open Stock Movers:

Limelight Networks (NASDAQ: LLNW) 21.5% LOWER; reported Q3 EPS of ($0.01), $0.03 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $59.2 million versus the consensus estimate of $58.94 million. Limelight Networks sees FY2020 EPS of ($0.02)-$0.08, versus the consensus of $0.08. Limelight Networks sees FY2020 revenue of $230-240 million, versus the consensus of $236.59 million.

yberoptics Corp (NASDAQ: CYBE) 19% LOWER; reported Q3 EPS of $0.24, $0.03 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.1 million.

Sassava Sciences (NASDAQ: SAVA) 18.4% HIGHER; Cantor Fitzgerald initiates coverage on with an Overweight rating and a price target of $24.00.

U.S. Xpress Enterprises (NYSE: USX) 16.8% LOWER; reported Q3 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $431.5 million versus the consensus estimate of $444.88 million.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) 15.9% LOWER; intends to offer and sell common shares and, to certain investors in lieu thereof, pre-funded warrants to purchase common shares, in an underwritten public offering. All of the securities in the offering will be sold by Milestone. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Solid Biosciences Inc. (Nasdaq: SLDB) 14.9% HIGHER; Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced a strategic collaboration and license agreement to focus on the development and commercialization of new gene therapies for Duchenne. The parties will collaborate to develop products that combine Solids differentiated microdystrophin construct, Ultragenyxs HeLa producer cell line (PCL) manufacturing platform, and AAV8 variants. The collaboration also brings together Solids expertise in muscle biology and Ultragenyxs expertise in bringing novel therapies to patients with rare diseases.

CTI BioPharma (NASDAQ: CTIC) 13.2% HIGHER; ​Brookline Capital Markets initiates coverage on with a Buy rating and a price target of $7.00.
Immutep Limited (NASDAQ: IMMP) 13% HIGHER; announced the start of an Investigator-Initiated Phase II study in COVID-19 patients

Boston Beer Co. (NYSE: SAM) 10% HIGHER; reported Q3 EPS of $6.51, $2.01 better than the analyst estimate of $4.50. Revenue for the quarter came in at $525.25 million versus the consensus estimate of $520.87 million. Boston Beer Co. sees FY2020 EPS of $14.00-$15.00, versus the consensus of $12.63.

eHealth (NASDAQ: EHTH) 9.5% LOWER; reported Q3 EPS of ($0.36), $0.22 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $94.3 million versus the consensus estimate of $87.35 million. eHealth sees FY2020 EPS of $3.83-$4.32, versus the consensus of $4.22. eHealth sees FY2020 revenue of $630-670 million, versus the consensus of $653.7 million.

Intel (NASDAQ: INTC) 9.5% LOWER; reported Q3 EPS of $1.11, in-line with the analyst estimate of $1.10. Revenue for the quarter came in at $18.3 billion versus the consensus estimate of $18.22 billion. Intel sees FY2020 EPS of $4.90, versus the consensus of $4.85. Intel sees FY2020 revenue of $75.3 billion, versus the consensus of $75.13 billion.

Manhattan Associates, Inc. (NASDAQ: MANH) 9.2% LOWER; reported Q3 EPS of $0.51, $0.12 better than the analyst estimate of $0.39. Revenue for the quarter came in at $149.8 million versus the consensus estimate of $138.87 million.

CASI Pharmaceuticals (NASDAQ: CASI) 7.5% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $5.00.

MeiraGTx Holdings plc (NASDAQ: MGTX) 7% HIGHER; RBC Capital initiates coverage with an Outperform rating and a price target of $27.00.

Mattel (NASDAQ: MAT) 6.8% HIGHER; reported Q3 EPS of $0.95, $0.57 better than the analyst estimate of $0.38. Revenue for the quarter came in at $1.63 billion versus the consensus estimate of $1.46 billion.

Gilead Sciences, Inc. (Nasdaq: GILD) 4.7% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury® (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19. Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States. The drug is now widely available in hospitals across the country, following early investments to rapidly expand manufacturing capacity to increase supply.

Seagate Technology (NASDAQ: STX) 4.4% LOWER; reported Q1 EPS of $0.93, $0.05 better than the analyst estimate of $0.88. Revenue for the quarter came in at $2.31 billion versus the consensus estimate of $2.34 billion. Seagate Technology sees Q2 2021 EPS of $0.95-$1.25, versus the consensus of $1.08. Seagate Technology sees Q2 2021 revenue of $2.35-2.85 billion, versus the consensus of $2.48 billion.

American Express (NYSE: AXP) 4.1% LOWER; reported Q3 EPS of $1.30, $0.11 better than the analyst estimate of $1.19. Revenue for the quarter came in at $8.75 billion versus the consensus estimate of $8.62 billion.

Fastly Inc. (NYSE: FSLY) 3.5% LOWER; Piper Sandler downgraded from Neutral to Underweight with a price target of $65.00 (from $84.00).

Hasbro, Inc. (NYSE: HAS) 3% HIGHER; up on MAT's results.

Capital One Financial (NYSE: COF) 2.6% HIGHER; reported Q3 EPS of $5.05, $3.04 better than the analyst estimate of $2.01. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $6.7 billion.

Categories

Special Reports

Next Articles